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Introduction
With regard to physicians’ abilities to treat short stature,
it has been just over 50 years since the first child in the
United States (US) with growth hormone (GH) deficiency
was treated with GH, initially of cadaveric pituitary origin (1).
Since 1985, only recombinant human GH (rhGH) has been
used to treat children with growth disorders of which there
are now nine FDA-approved indications (some associated
with GH deficiency and others with presumed GH 
resistance), the most controversial of which is idiopathic
short stature (ISS). As highlighted in the recent book,
Normal At Any Cost by Cohen and Cosgrove (2), there has
been a push to create a taller society among parents and
physicians. To accomplish such a goal, there is now 
available an expanding pharmacological repertoire that
includes direct growth-promoting agents such as rhGH and,
now, insulin-like growth factor-I (IGF-I) in the US and in
Europe, and, historically, anabolic steroids, mostly used 
outside the US. An alternative approach to height 
augmentation employs agents that impede puberty and, in
particular, estrogen production (in both sexes), which is
responsible for ultimate epiphysial fusion. This approach
has, traditionally, employed gonadotropin-releasing 
hormone (GnRH) agonists (GnRHa) and, more recently, 
aromatase inhibitors (AIs). These approaches have been
used as sole treatments or in various combinations, with
varying efficacy and safety profiles. 
For example, in a study by Yanovski et al from US, use
of a GnRHa alone in 26 short adolescent males with 
normally timed puberty for a mean of 3.5 years increased
height by 0.6 SD, but substantially decreased bone mineral
density (BMD) (3). Carel from France in 2006 wrote that,
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outside the context of precocious puberty, yields some
height gains and that GH alone modestly increases adult
height in short adolescents with ISS or in those born small
for gestational age (SGA), combination therapy lacks proof
of additional efficacy (4). In that vein, a Dutch study of 
combined GH and GnRHa therapy failed to show any 
difference in final height after 3 years (compared to a 
no-treatment control group) in either short adolescent
males born SGA or with ISS  (5). However, Tanaka from
Japan recommends combined GH and GnRHa treatment in
short GH- or non-GH-deficient children who start puberty at
a short height (6). 
Thus, it seems that most investigators do not advocate
routine combination growth-promoting therapy for normal
short children, but espouse the need for further study via
large randomized controlled trials to assess efficacy and
safety, as well psychological benefits and economic 
viability. That said, with the availability of AI’s, the first new
class of potential oral growth-promoting agents, many short
(or predicted to be short) children are being treated with
this class of drug, either as mono-therapy or as part of
multi-drug regimens.
Role of Androgens and Estrogens in 
Growth Promotion
To understand the rationale for AI treatment, it is 
important to first review the historical understanding of the
general physiological roles of androgens and estrogens in
the 1980s. In that era, it was thought that, in males, 
testosterone was the principal sex hormone responsible for
the pubertal growth spurt, skeletal maturation, accrual of
bone mineral, and maintenance of skeleton (anti-
osteoporotic action). Conversely, it was believed that estrogen
was not an important regulator of follicle stimulating hormone
(FSH) secretion and had a trivial role in non-reproductive 
tissues. Finally, it was also believed that local conversion of
testosterone to estradiol in the brain exerted an important
effect on psychosexual differentiation (7). However, the
identification of two men, one with a mutation of the estrogen
receptor gene (8) and another with a mutation of the 
aromatase gene (9), taught us differently. Similarities and
differences (in italics) between these two pristine cases are
described in Table 1 (9). That both cases were associated
with lack of estrogenic signaling caused a 
paradigm shift underscoring the critical role of estrogen
(presumably in both sexes) in epiphysial maturation/closure
and on gonadotropin regulation.
Aromatase Physiology
Furthermore, these cases brought to light the possibility
of a new understanding of physiology which could be
applied to growth manipulation in boys predicted to have
short adult height, i.e., intentional pharmacological blockade
of aromatase-driven conversion of androgens to estrogens.
To better understand this rationale, it is critical to note that
the human aromatase enzyme is a cytochrome P450 
hemoprotein-containing enzyme located in the endoplasmic
reticulum of estrogen-producing cells located in many 
tissues. These include osteoblasts and chondrocytes in
bone, stromal cells of fat, Leydig and germ cells of testes
(in males), smooth muscle cells of the vasculature, and 
several areas of the hypothalamus, limbic system, and 
cerebral cortex. Note that the aromatase enzyme catalyzes
the rate-limiting step in conversion of androgens to 
estrogens and is encoded by a single gene, CYP19, located
on chromosome 15q21.2 (10).
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Table 1. Comparison of estrogen receptor-α deficiency (ERKOα) and of aromatase deficiency
28-year-old male (ERKOα α) 24-year-old male (P450arom)
Height 204 cm, weight 127 kg Height 204.7 cm, weight 135.1  kg
No acromegaloid features No acromegaloid features
Eunuchoid skeletal proportions; genu valgum Eunuchoid skeletal proportions
Normal age of puberty onset Normal age of puberty onset
Well-masculinized;  normal testicular size Well-masculinized; testicular volume 34 mL
Bone age 15 years old Bone age 14 years
Severe osteoporosis; increased bone turnover Severe osteoporosis; increased bone turnover
Psychosexual orientation:  heterosexual Psychosexual orientation:  heterosexual
No virilization of mother during pregnancy Virilization of mother during pregnancy
Insulin resistance; acanthosis Insulin resistance
Abnormal plasma lipids Abnormal plasma lipids
No response to high-dose estrogen treatment Striking response to of low-dose estrogen therapy
Inheritance: autosomal recessive Inheritance:  autosomal recessive
Mutation:  Arg157X (Exon 2)in ERαgene Mutation: Arg376Cys (EXON IX) in CYP19 geneConveniently, the class of drugs known as AIs was
already on the market in the US to adjunctively treat 
estrogen receptor-positive breast cancer, their sole FDA-
approved indication. More specifically, AIs prevent conversion
of the C19 androgenic steroids, androstenedione (A) 
and testosterone (T), to their C18 estrogenic counterparts,
estrone (E1) and estradiol (E2), respectively. They also 
block conversion of estrogens to catechol estrogen, 
2-hydroxyestrogen, and 6α-hydroxyestrogen, metabolites
which may have critical roles in induction or promotion of
estrogen-responsive malignancies. There are two classes
of AIs, non-steroidal and steroidal, as well as three 
generations. The former reversibly bind to the heme moiety
of the cytochrome P450 aromatase enzyme, while the 
latter are derivatives of A that act irreversibly as false or 
“suicide” substrates for the aromatase enzyme (11). The
categorization of AIs can be found in Table 2, along with
clinical comments about their toxicity. The generational 
differences among the AIs show that, with newer 
generations, progressively lower doses are needed to
achieve a higher efficiency of enzymatic blockade (Table 3).
Use of Aromatase Inhibitors in Children
Critical research in the pediatric literature as it applies to
AI use for height purposes will be reviewed in temporal
sequence. Other clinical conditions in childhood in which
AIs have been used, e.g., McCune-Albright syndrome,
testotoxicosis, congenital adrenal hyperplasia, and pubertal
gynecomastia, will not be discussed (12-16). 
The first reported use of AIs to assess their effect on
height (17) was in a group of 33 Finnish adolescent boys
(mean age 15 yr) with constitutional delay of growth and
puberty (CDGP) who were randomized to receive either:
intramuscular depot T (1 mg/kg every 4 weeks for 6
months) and letrozole (2.5 mg/d) for 12 months (n=11); 
T and placebo for 12 months (n=12); or no treatment
(n=10). After 12 months, serum E2 levels in those patients
on letrozole were maximally suppressed and serum T levels
were maximally increased. Mean bone age (BA) 
advancement was desirably and significantly less in the
group treated with T and letrozole (only 0.9 years) vs T and
placebo (1.7 years) and no treatment (1.1 years). This 
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Table 2. Aromatase inhibitor classes
Generation Non-steroidal/ Reversible Steroidal/Irreversible Comments
First Aminogluthemide Substantial morbidity (lethargy, rashes, nausea, and fever) 
and lack of selectivity for aromatase enzyme, which 
resulted in medical adrenalectomy
Testolactone First AI extensively investigated for treatment of 
advanced breast cancer
Second Fadrazole Formestane Formestane had fewer side effects, but required 
2X-monthly IM dosing and was associated with local 
reactions in 17%
Third Anastrazole Exemestane 3
rd-generation agents more specific for aromatase enzyme, 
fewer side effects, and longer-acting for once-daily dosing
Letrozole
Vorozole
Reversibly bind to heme moiety of  Derivatives of A that act as false
cytochrome P450 enzyme substrates and bind irreversibly
(suicide substrates)
Table 3. Relative Potency of select aromatase inhibitors
Compound Dosage % Aromatase inhibition
Aminoglutethimide 250 mg 4 times daily 90.6
Testolactone 10 mg/kg 4 times daily <90.0
Formestane 125 mg twice daily 91.9
Fadrozole 2 mg twice daily 92.6
Anastrozole 1 mg once daily 97.3
Letrozole 2.5 mg once daily >99.1difference resulted in a mean increase in predicted adult
height of 5.1 cm in the group receiving T and letrozole,
which was significantly more than in the other two groups.
The first report of AI use in children from the US in 2003
described the pharmacokinetic properties of exemestane in
12 healthy eugonadal adolescent and young adult males
between the ages of 14-26 years of age over a 10-day 
period  (18). The investigators found that 25- and 50-mg
doses of exemestane had similar effects on all parameters
measured, including estrogen (32-38% decrease), testosterone
(~60% increase), sex hormone binding globulin (SHBG) 
(19-21% decrease), and dehydroepiandrosterone (DHEA) 
sulfate (no change). Further studies to investigate 
pharmacokinetics of a single oral 25-mg dose of exemestane
noted peak absorption at 1 hour with a terminal half-life of
8.9 hours. In addition, mean serum E2 levels were maximally
suppressed at 12 hours and returned to baseline after 3-6
days.                       
In a retrospective study of 18 non-testosterone-treated
adolescent males with limited growth potential (mean age
15 years) and rapidly advancing BA, Karmazin et al reported
that treatment solely with letrozole, 2.5 mg orally daily
(mean duration 12.4 months), resulted in a slow down in BA
advancement compared to the rate seen prior to initiation of
treatment (mean change in BA to chronological age = 0.68
vs 1.57 years), thus explaining an increased mean predicted
adult height in the letrozole-treated group (-0.64 vs -1.41
SD) (both p<0.0005) (19). 
In a follow-up study of the previously described group of
Finnish boys with CDGP, Hero et al reported mean 
near-adult heights of 175.8 cm and 169.5 cm (p=0.04) and
mean gains in height SD scores of 1.4 and 0.8 (p=0.03) in
the T and letrozole vs the T and placebo groups, 
respectively (20).
In the largest and longest US study to date, Mauras et
al randomized 52 adolescent males with GH deficiency to
treatment with GH and either daily co-treatment with 
anastrozole or placebo for up to 36 months (21). Of the original
cohort, 50 subjects completed 12 months, 41 
completed 24 months, and 28 completed 36 months. At
study completion, linear growth was comparable between
both groups; however, after 2 years, there was a 
significantly slower mean increase in BA advancement
from baseline in the anastrozole vs the placebo group (+1.8
vs +2.78 years, p<0.0001) and after 3 years (+2.58 vs +4.18
years, p<0.0001). This difference resulted in a net increase
in mean predicted adult height of 4.5 cm in the anastrozole
group at 24 months and 6.8 cm at 36 months compared
with a 1-cm gain at both time points in placebo group.
During the course of the study, all boys on AIs had a normal
tempo of pubertal virilization and, as expected, E2 and E1
concentrations increased less in the anastrozole vs the
placebo group.
Safety of Aromatase Inhibitors
In the Finnish trials (17,22,23), over the first 2 years of
study, no differences in the rate of occurrence of adverse
events between treatment groups were recorded involving
multiple safety parameters, including lipids, adiponectin,
GH surrogates, insulin sensitivity by homeostatic model
assessment (HOMA), skinfold thickness, and BMD, with
the exception of reduced levels of HDL cholesterol and fat
mass in the letrozole-treated group. Of note, however,
mean T levels were 455 ng/dL in T and placebo, and 1415
ng/dL in T and letrozole at 12 months. In the longer term
study of this cohort, Hero et al showed an increase in bone
mineral apparent density (employing a volumetric 
correction) by DEXA scan in letrozole-treated boys with ISS
after 2 years, but not in the placebo-treated group (24).
Furthermore, in the study of Karmazin et al, ~25% of 
letrozole-treated subjects showed asymptomatic 
biochemical evidence of adrenal suppression (19). 
Additional theoretical adverse effects of induced 
estrogen depletion and/or androgen excess (for which data
exist) must also be considered (16). With regard to possible
growth suppression, Hero et al has reported lower serum
IGF-I levels in letrozole-treated teenagers (25). Possible
effects of this altered hormonal milieu on cognition are
based on three pieces of information. First, verbal memory
and estrogen levels have been noted to change in parallel
during the menstrual cycle. Second, in a cross-sectional
study of women with breast cancer, those treated with
anastrazole performed poorly on tests of verbal memory
function compared to controls. Third, healthy older men
treated with testosterone improved spatial and verbal
memory, findings negated with addition of anastrazole.
Perhaps the area that needs the most consideration is
the possible long-term effect on spermatogenesis and 
fertility. Such concerns are based on the fact that estrogen
receptor-α knock-out male mice show progressive 
impairment of fertility due to loss of the fluid resorptive
function in epithelial cells of efferent ductules, resulting in
their swelling and swelling of the rete testes (26). In 
addition, male aromatase knock-out mice have impaired
spermatogenesis in older age. Furthermore, treatment of
male monkeys with letrozole reduces sperm count and
quality. In contradistinction, infertile men with low T:E2
ratios had improved sperm count and quality after 
treatment with anastrazole. Specifically with regard to
potential reproductive effects of AI use in adolescent
males, Mauras et al examined sperm concentration, 
motility, and morphology in 11 adolescent males (mean age
18.1 years) with GH deficiency treated with anastrazole 29
months prior on average and found no differences 
compared to controls, although sperm counts were 
somewhat low in both groups, raising into question validity
of their laboratory methodology (27).
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letrozole-treated boys showed an initial increase followed
by a slow declined in the bone resorption marker, urine
aminoterminal telopeptide of type I collagen, while serum
concentrations of the bone formation markers, s-PINP and
alkaline phosphatase remained unchanged (25). In contrast,
all markers of bone turnover increased significantly in the
placebo-treated boys. In addition, increased concentrations
of androgens have been shown to inhibit osteoclast 
differentiation and bone resorption in humans, as well as in
cultured human osteoclasts.
A new concern that has recently arisen is the possible
effect of AIs on vertebral morphology. Hero et al recently
reported the detection of asymptomatic or mildly 
symptomatic vertebral wedge deformities in boys with ISS
previously treated with letrozole vs placebo (25). Using Dual
X-ray Absorptiometry-Instant Vertebral Assessment 
(DXA-IVA), wedge deformities were classified as mild
(Grade 2a) when anterior vertebral height reduction is
>20%, but <50%, and as severe (Grade 2b), when 
reduction is >50%. In mild and severe compression 
deformities, anterior, middle, and posterior vertebral
heights are decreased by 20-30% (Grade 3a) and by >30%
(Grade 3b), respectively. Of note, 6/13 (46%) letrozole-treated
boys and 4/11 (36%) placebo-treated boys had 14 and 9
involved vetrebrae, respectively, of which most were
Grades 2a and 3a in both groups. Although there was no
statistical difference between the occurrence rate in the
two groups, baseline studies were not performed. Thus, in
ISS, some boys may have a defect of bone metabolism that
impairs both bone growth and strength and results in 
anterior vertebral wedge deformity. Further studies on the
impact of aromatase inhibition on bone architecture and
vertebral morphology are clearly needed.
Theoretical effects of estrogen depletion and/or 
androgen excess by AIs, for which meaningful data do not
exist, might include a possible effect on sexual orientation.
Finally, the possible use of AIs in girls has not been studied,
although induced hyperandrogenemia in females would be
likely to severely limit their use.
Summary and Conclusions
As of the end of 2008, results (with none to adult height)
from only ~110 children worldwide with short stature 
treated with a variety of third-generation AIs (and usually
other growth-promoting therapy) have been reported and
only three randomized, double-blinded, placebo-controlled
trials have been performed. Five of the original seven
reports derive from the same two research groups and two
of those involve same initial patients. There has been only
one small prospective randomized trial of AIs as sole 
therapy in adolescent males with ISS, but none in boys with
CDGP. Only nine patients have been followed to near-final
height and there are no available data regarding adult
heights from any of the controlled trials. Moreover, one of
the studies involving patients with GH deficiency found no
change in mean predicted adult height among patients who
were treated with AIs. 
It appears that these formulations are well-tolerated
and, over relatively short time periods (12-18 months), no
“significant” side effects have been reported. While 
(theoretical) concerns remain regarding BMD accrual, bone
morphology, HDL concentrations, spermatogenesis, 
cognitive function, and the metabolic effects of decreased
circulating estradiol, AIs have been promising in delaying
BA advancement and, in most, but not all studies, in
improving predicted adult height.
If proven efficacious and safe, AIs would be a useful
new pharmacological intervention for boys with rapid BA
advancement, various forms of precocious puberty, and/or
CDGP. However, due to the dearth of scientific data 
currently available on the long-term efficacy and safety of AI
treatment in children and adolescents, the use of such 
therapy outside of research settings should be discouraged.
Thus, well-designed, long-term studies of efficacy and 
safety of AIs are required and should be supported by the
pharmaceutical industry and/or other granting agencies.
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